Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?

Future Oncol. 2020 Jul;16(19):1327-1330. doi: 10.2217/fon-2020-0311. Epub 2020 May 12.

Navid Sobhani^{1

2}, Silvia P Corona¹, Giandomenico Roviello¹, Stefan Bagby³, Alberto D'Angelo³, Giandomenico Iezzi⁴, Daniele Generali^{1

5}

¹ Department of Medical, Surgery & Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.
² Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, 77030 Houston, TX, USA.
³ Department of Biology & Biochemistry, University of Bath, BA2-7AX Bath, United Kingdom.
⁴ Institute for Research in Biomedicine (IRB), Murate Building, Via Murate 5A, 6500 Bellinzona, Switzerland.
⁵ Breast Cancer Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

No abstract available

Keywords: checkpoint inhibitors; immune markers; immune-gene signature; solid tumors.

Publication types